13 articles
Bristol Myers Squibb plans a $2.3 billion drug manufacturing facility in Houston to produce small-molecule and biologic medicines, creating nearly 500 skilled jobs as part of a broader U.S. investment
AstraZeneca and Bristol Myers Squibb denied merger talks, dispelling rumors of a $400 billion deal that previously caused significant share price movements.
An editorial advises AstraZeneca against a proposed $400bn merger with Bristol Myers Squibb, recommending it stick to its organic growth strategy rather than high-risk financial engineering. Concerns
Gulf chemical manufacturers continue operations despite regional conflicts, while Bristol Myers Squibb and AstraZeneca are reportedly exploring a merger.
Japan and the US executed a historic $60 billion joint yen intervention to stabilize the currency. Concurrently, oil prices fell 5% on geopolitical developments, while AstraZeneca shares dipped amid p
US stocks hit record highs as Iran talks reduced oil prices by 5%, while Bristol Myers Squibb and AstraZeneca began merger talks potentially forming a $400 billion drugmaker.
Financial Times reports AstraZeneca and Bristol Myers Squibb are exploring a potential $400 billion merger to create a top global pharmaceutical group. Recent strong sales in oncology and rare disease
Bristol Myers Squibb raised its full-year revenue and profit forecast after second-quarter results exceeded Wall Street estimates, driven by strong sales of Eliquis and newer medicines like Camzyos an
Bristol Myers Squibb paid Jiangsu Hengrui Pharmaceuticals $600 million upfront to license therapeutic molecules, highlighting China's shift from generic to novel drug innovation.
The American Chemical Society appointed Pamela Fisher as Senior Vice President of Inclusion and Belonging. She joins from Bristol Myers Squibb to lead diversity strategy and foster inclusive scientifi
Bristol Myers Squibb partners with Anthropic to deploy Claude AI across 30,000 employees to accelerate drug discovery and manufacturing. The initiative aims to leverage agentic AI to potentially boost
Bristol Myers Squibb has partnered with Chinese drugmaker Hengrui Pharmaceuticals in a deal potentially worth up to $15.2 billion, featuring a $600 million upfront payment and milestone options.
Bristol Myers Squibb exceeded Q1 profit expectations on strong Eliquis and cancer drug sales, boosting shares 4%. It reaffirmed its 2026 outlook and intends to leverage AI to accelerate drug discovery
ChemBrief